secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001193125-26-079500
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ACR-368 interim data from registrational-intent arms presented at ESGO for endometrial cancer serous subtype
--------------------------------------------------------------------------------

- Interim data from ACR-368 Phase 2b registrational-intent trial presented at ESGO Congress on February 27, 2026.
- Data focused on endometrial cancer, particularly the serous sub-type.
- KOL panel discussed potential of ACR-368 to address unmet need in this patient population.
- Company-sponsored webcast with on-site and virtual participation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312526079500/0001193125-26-079500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312526079500/d116670d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-079500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer